Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

for
Solid Tumor, Adult, Solid Tumor, Melanoma, Basal Cell Cancer,
Location: Denver CO, Nashville TN
Sponsor: Rise Therapeutics LLC

Sex: All

Age: 18 - 70+

Code: NCT06398418

Phase 1, Recruiting

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

for
Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors,
Location: Washington D.C. DC, Sarasota FL, Atlanta GA, Houston TX,
Sponsor: Avenzo Therapeutics, Inc.

Sex: All

Age: 18 - 70+

Code: NCT07038343

Phase 1, Phase 2, Recruiting

Imaging of Solid Tumors Using 18F-TRX

for
Solid Tumor, Solid Carcinoma,
Location: San Francisco CA
Sponsor: Rahul Aggarwal

Sex: All

Age: 18+

Code: NCT06942104

Phase 1, Recruiting

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

for
Clinical Stage III Gastric Cancer AJCC v8,
Location: Houston TX
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06364410

Phase 1, Recruiting

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

for
Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer,
Location: Boston MA, Goodyear AZ, Duarte CA
Sponsor: I-Mab Biopharma US Limited

Sex: All

Age: 18+

Code: NCT07432295

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for
Advanced Malignant Solid Neoplasm,
Location: Brewer ME, Augusta ME, Scarborough ME,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase 2, Recruiting

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

for
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT03412877

Phase 2, Recruiting

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

for
Neoplasms, Brain, Glioblastoma Multiforme,
Location: Birmingham AL, St Louis MO, Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 3 - 22

Code: NCT03911388

Phase 1, Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

for
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Location: New York NY, Jacksonville FL, Ann Arbor MI, Chicago IL,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06401356

Phase 3, Recruiting

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

for
Advanced Solid Tumor,
Location: Boston MA, Lebanon NH, Morristown NJ,
Sponsor: Vaxiion Therapeutics

Sex: All

Age: 18+

Code: NCT05901285

Phase 1, Recruiting

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

for
Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor,
Location: Boston MA, New Haven CT, New York NY, Hickory NC,
Sponsor: Exelixis

Sex: All

Age: 18+

Code: NCT06952010

Phase 1, Recruiting

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

for
Breast Cancer, Breast Cancer Metastatic,
Location: Boston MA, Durham NC, Buffalo NY, Orlando FL,
Sponsor: Incyclix Bio

Sex: All

Age: 18+

Code: NCT05735080

Phase 1, Phase 2, Recruiting

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

for
Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood
Location: Valhalla NY, The Bronx NY, Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All

Age: 1 - 40

Code: NCT03465592

Phase 1, Phase 2, Recruiting

Immune Resistance Interrogation Study

for
Cancer, Solid Tumor, Metastatic Cancer, Immune Resistance
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT04243720

Recruiting

Circulating Tumor DNA Exposure in Peripheral Blood

for
Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer,
Location: Orlando FL, Celebration FL, Centerville OH, Dayton OH
Sponsor: Quantgene Inc.

Sex: All

Age: 18+

Code: NCT03517332

Recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

for
Non-Small Cell Lung Cancer, NSCLC,
Location: Boston MA, New Haven CT, New York NY, Tampa FL,
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All

Age: 18+

Code: NCT06917079

Phase 1, Recruiting

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

for
Non-small Cell Lung Cancer,
Location: Boston MA, New York NY, New Brunswick NJ, Pittsburgh PA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT05877599

Phase 1, Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

for
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC),
Location: Boston MA, New Haven CT, New York NY, Baltimore MD,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06040541

Phase 1, Recruiting

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

for
Advanced Solid Tumor, Unresectable Solid Tumor,
Location: New York NY, Hackensack NJ, Philadelphia PA,
Sponsor: Clasp Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06778863

Phase 1, Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

for
Advanced Cancer, Metastatic Cancer, Ovarian Cancer,
Location: Boston MA, Lake Success NY, New York NY,
Sponsor: Artios Pharma Ltd

Sex: All

Age: 18+

Code: NCT04657068

Phase 1, Phase 2, Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial